Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardio Diagnostics HoldingsCDIO +0.15%49 PS Ratio is 174.44 as of Jul. 30, 2026, which is 46% below its 10-year median of 323.53. GuruFocus rates CDIO with a GF Score™ of 49/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Cardio Diagnostics Holdings ranks worse than 89.57% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cardio Diagnostics Holdings's share price is $1.57.
Cardio Diagnostics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.01. Hence, Cardio Diagnostics Holdings's PS Ratio for today is 174.44.
The historical rank and industry rank for Cardio Diagnostics Holdings's PS Ratio or its related term are showing as below:
CDIO'
s PS Ratio Range Over the Past 10 Years
Min: 98.15 Med: 323.53 Max: 68800
Current: 174.46
During the past 6 years, Cardio Diagnostics Holdings's highest PS Ratio was 68800.00. The lowest was 98.15. And the median was 323.53.
CDIO's PS Ratio is ranked worse than 89.57% of 930
companies
in the Biotechnology industry
Industry Median: 8.89
vs CDIO: 174.46
During the past 6 years, Cardio Diagnostics Holdings's highest 3-Year average Revenue per Share Growth Rate was 135.10% per year. The lowest was -3.50% per year. And the median was 65.80% per year.
Back to Basics: PS Ratio
Cardio Diagnostics Holdings (NAS:CDIO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cardio Diagnostics Holdings PS Ratio Related Terms
Cardio Diagnostics Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardio Diagnostics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cardio Diagnostics Holdings's Share Price of today is $1.57. Cardio Diagnostics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cardio Diagnostics Holdings (CDIO) has a PS Ratio of 174.44 as of Jul. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cardio Diagnostics Holdings and its competitors. This is 46% below median its historical median of 323.53. Over the past decade, Cardio Diagnostics Holdings' PS Ratio has ranged from 98.15 to 68,800.00. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #833 out of 930 companies in the Biotechnology industry, placing it in the top 89.6%.
Is Cardio Diagnostics Holdings' PS Ratio too high?
Cardio Diagnostics Holdings' current PS Ratio of 174.44 is 46% below median its 10-year median of 323.53. Over the past 10 years, this metric has ranged from a low of 98.15 to a high of 68,800.00. The Biotechnology industry median PS Ratio is 8.89. Cardio Diagnostics Holdings' value of 174.44 is 1862.2% above this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #833 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' PS Ratio compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #833 out of 930 companies for PS Ratio. This places Cardio Diagnostics Holdings in the lower half of its industry. The industry median PS Ratio is 8.89. Cardio Diagnostics Holdings' value of 174.44 is 1862.2% above this benchmark. Historically, Cardio Diagnostics Holdings' own PS Ratio has ranged from 98.15 to 68,800.00 over the past decade. While the company's 10-year median is 323.53 vs. the industry median of 8.89, Cardio Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.89, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current PS Ratio of 174.44 is 1862.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 8.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current PS Ratio is 174.44, which is 46% below median its own 10-year median of 323.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.3% below its estimated fair value. The current PS Ratio is 174.44, which is 46% below median its 10-year median of 323.53 and 1862.2% above the Biotechnology industry median of 8.89. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current PS Ratio is 174.44 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued.
The current stock price of $1.57 is trading 43.3% below its estimated GF Value™ of $2.77.
GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.
Key valuation signals for CDIO:
PS Ratio: 174.44 (46% below median its 10-year median of 323.53)
GF Value™: $2.77 vs. price of $1.57 (43.3% below fair value)
Industry Position: 1862.2% above the Biotechnology median (#833 of 930)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score
Get the complete analysis for CDIO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
